Mathias Oelke Email

CSO - Head Preclinical Immunotherapy and Platform Development . NexImmune

Gaithersburg, MD

Location

Current Roles

Employees:
45
Revenue:
$7M
About
NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIMâ„¢ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body's own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient's immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient's body.
NexImmune Address
9119 Gaither Road
Gaithersburg, MD
United States
NexImmune Email

Past Companies

NexImmune, Inc.CSO - Head of Preclinical Immunotherapy and Platform Development

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.